Nexalin Technology, INC

Nexalin Technology, Inc. has amended its office lease to extend the term and expand its headquarters in Houston, Texas.

Nexalin Technology, Inc. has received a delisting notice from Nasdaq due to failure to meet minimum bid price and stockholders equity requirements, with an appeal pending.

Nexalin Technology, Inc. has adopted Second Amended and Restated Bylaws, revising corporate governance procedures including stockholder meeting requirements and director nominations.

Nexalin Technology acquires PONM, Inc. to integrate AI-driven digital health platform supporting its HALO Clarity program and NeuroCare virtual clinic.

Nexalin Technology has engaged Lindus Health to conduct a 160-participant pivotal clinical trial for its HALO Clarity device to support a De Novo FDA submission.

Nexalin Technology, Inc. announced the advancement of its pivotal clinical trial for the HALO Clarity device, targeting moderate to severe insomnia, to support a planned de novo FDA submission.

Nexalin Technology reports a net loss of $2.1 million for Q1 2026 while advancing clinical trials for its neurostimulation devices.

Nexalin Technology reports a narrower net loss in Q3 2025, driven by reduced operating expenses, while securing a significant FDA Q-Submission acceptance for its Gen-2 SYNC system targeting Alzheimer's and dementia.

Nexalin Technology, Inc. reported a significant increase in net loss for Q2 2025 and the first half of 2025, driven by higher operating expenses, despite revenue growth and a successful capital raise.

Nexalin Technology's Q1 2025 results show a decrease in revenue compared to Q1 2024, coupled with increased operating expenses, particularly in research and development.

Nexalin Technology's Q3 2024 report reveals increased revenue but ongoing losses, alongside efforts to navigate regulatory hurdles and maintain Nasdaq listing compliance.

Nexalin Technology's Q2 2024 report details financial results, ongoing regulatory efforts, and strategic developments in the neurostimulation device market.

Nexalin Technology, Inc. reported significant operating losses and a going concern warning, alongside Nasdaq minimum bid price non-compliance, despite advancing its neurostimulation product pipeline.

Nexalin Technology, Inc. filed an amendment to its annual report, correcting internal control disclosures and refiling financials that show increased revenue but also widening net losses and persistent going concern doubts.

Nexalin Technology files an amendment to its 2024 annual report to include the Insider Trading Policy and Compensation Recoupment Policy exhibits.

Nexalin Technology's 10-K filing reveals ongoing efforts to develop and commercialize neurostimulation products for mental health, while addressing regulatory hurdles and financial challenges.

Nexalin Technology's 2023 annual report highlights a shift towards next-generation device development and regulatory approvals, with a focus on new clinical trials and a virtual clinic model.

Nexalin Technology CEO Mark White was granted 1,000,000 stock options with an exercise price of $0.83, exercisable immediately.

Nexalin Technology's CFO, Justin Van Fleet, was granted 100,000 stock options at an exercise price of $0.83, exercisable immediately.

Nexalin Technology's Chief Medical Officer, David Owens, was granted 1,000,000 stock options at an exercise price of $0.83, effective December 19, 2025.

Nexalin Technology's Sr. VP of Quality and Regulatory, Carolyn Shelton, was granted 100,000 stock options at an exercise price of $0.83, subject to shareholder approval.

Nexalin Technology Director Ben Hu received a grant of 100,000 stock options at an exercise price of $0.83, exercisable from December 19, 2025.

Nexalin Technology Director Alan Kazden was granted 100,000 stock options at an exercise price of $0.83, contingent on future shareholder approval.

Nexalin Technology announces its 2026 Annual Meeting of Stockholders, detailing proposals including director elections, equity plan approval, reverse stock split, preferred stock authorization, officer exculpation, and auditor ratification.

Nexalin Technology, Inc. has announced its virtual-only Annual Meeting of Stockholders for July 15, 2025, where shareholders will vote on the election of five directors, an amendment to increase shares reserved under its 2023 Equity Incentive Plan, and the ratification of CBIZ CPAs P.C. as independent auditors.

Nexalin Technology will hold its annual stockholder meeting virtually on August 26, 2024, to elect directors, approve an equity incentive plan amendment, and ratify the appointment of independent auditors.

Nexalin Technology is filing an amendment to its Form S-1 registration statement to allow selling stockholders to resell up to 2,798,613 shares of common stock.

Nexalin Technology has filed an amendment to its S-1 registration statement to allow selling stockholders to resell up to 2,798,613 shares of common stock.

Nexalin Technology has filed an S-1 registration statement for the resale of up to 2,798,613 shares of common stock by selling stockholders, primarily related to warrants issued in connection with their 2022 public offering.

Nexalin Technology is seeking to raise up to $7 million by offering common stock at an assumed price of $2.26 per share, aiming to bolster its financial position and advance its neurostimulation technology.

Nexalin Technology is seeking to raise up to $7 million through a best-efforts offering of its common stock, aiming to fund general corporate purposes and advance its neurostimulation technology.

Nexalin Technology aims to raise up to $7 million through a common stock offering to fund general corporate purposes.